SPDR® S&P Biotech ETF
XBI holdings: the top 10 right now
XBI's top 10 holdings make up only 18.7% of the fund, and the largest, Moderna Inc, is 2.4% as of 20 November 2026. That is because XBI gives each biotech company roughly the same weight, so its top 10 is mostly the companies that rose most since the last rebalance.
Holdings and prices as of 20 November 2026. Updated after each market close.
What XBI holds now
XBI, the SPDR S&P Biotech ETF, tracks the S&P Biotechnology Select Industry Index: US-listed biotech companies, from the industry's giants down to small drug developers with no product on sale yet. As of 20 November 2026, these are its ten largest positions.
| # | Holding | Sector | Weight |
|---|---|---|---|
| 1 | Moderna IncMRNA | Healthcare | 2.42% |
| 2 | Regeneron Pharmaceuticals IncREGN | Healthcare | 1.88% |
| 3 | Spyre Therapeutics Inc.SYRE | Healthcare | 1.84% |
| 4 | Amgen IncAMGN | Healthcare | 1.83% |
| 5 | Gilead Sciences IncGILD | Healthcare | 1.83% |
| 6 | Exelixis IncEXEL | Healthcare | 1.83% |
| 7 | AbbVie IncABBV | Healthcare | 1.77% |
| 8 | Biogen IncBIIB | Healthcare | 1.77% |
| 9 | United Therapeutics CorporationUTHR | Healthcare | 1.74% |
| 10 | TG Therapeutics IncTGTX | Healthcare | 1.74% |
The top 10 make up 18.7% of XBI’s 157 holdings. Weights as of 20 November 2026.
Why the weights are almost flat
Most large ETFs weight companies by their market value, so the biggest firms dominate. XBI does the opposite. Its index gives every company roughly the same weight and resets them to that level at each quarterly rebalance. A small company working on one drug counts about as much as Amgen or AbbVie.
That is why the top 10 makes up only 18.7% of the fund and the largest holding, Moderna Inc, is just 2.4%. Compare that with XLV, a health care fund weighted by size, where a single drug maker carries far more of the fund than any company does here.
The top 10 is a list of recent winners
In a size-weighted fund, the top of the table tells you which companies are the biggest. In XBI it tells you something else: which companies rose the most since the last reset. Every holding starts each quarter near the same weight, so the ones that climbed fastest drift to the top and the ones that fell drift to the bottom.
That has two effects most holdings lists don't mention. First, the top 10 changes often. Lists published only days apart show different names in the lower seats, and the whole order is reshuffled at each rebalance. Second, the top 10 is not where XBI's money is. With 157 holdings, most of the fund sits outside it, largely in small and mid-sized companies.
Healthcare makes up the whole fund, as you would expect from a one-industry ETF. The spread here is across companies, not sectors.
The top 10 against the whole fund
The backtest holds XBI's current top 10 at their fund weights, rescaled to the whole portfolio and rebalanced every quarter, and compares that with holding XBI itself. The comparison covers one, five and ten years for XBI itself; when one of the top 10 has traded for less than ten years, the basket's ten-year figure is left blank.
| 1 year | 5 years | 10 years | |
|---|---|---|---|
| Ending value of $10,000 | |||
| Top 10 basketTop 10 | $22,436 | $31,479 | — |
| XBI | $12,368 | $11,827 | $21,420 |
| Yearly return | |||
| Top 10 basketTop 10 | 124.5% | 25.8% | — |
| XBI | 23.7% | 3.4% | 7.9% |
| Worst drop | |||
| Top 10 basketTop 10 | 9.2% | 33.9% | — |
| XBI | 17.3% | 47.7% | 63.9% |
Windows end 20 November 2026. The top 10 are held at their fund weights rescaled to 100% and rebalanced quarterly; dividends are included on both sides. The top 10 basket has no 10-year figure because one of its stocks has traded for less time than that. Hypothetical results: past performance does not predict future returns.
Over five years the top 10 basket returned 25.8% a year against 3.4% for XBI, a gap of +22.4 points a year. Over the last year the gap was wider still, as the table shows.
Treat that gap with more care than usual. In an equal-weight fund, today's top 10 is close to a list of the companies that have just done best, so a backtest of it is built on hindsight. It says almost nothing about how those ten will do next. The fund's own record shows how hard biotech can be: XBI returned 23.7% over the last year, but only 3.4% a year over five, and its worst fall in that time was 47.7% from its high.
Before you copy the top 10
- Ten names is a small slice. A basket of ten biotech companies carries far more single-drug risk than a fund of well over a hundred.
- Equal weight is the strategy. If you want XBI's balance in your own version, use equal weights and rebalance them. Copy today's weights and let them drift, and the basket becomes a bet on whatever keeps rising.
- Big or small biotech. The large drug makers in the table behave very differently from the small developers below them. Try a version with only the large names, and one without them, and compare.
- Costs and taxes. XBI charges an annual fund fee. A basket of shares has no fund fee but has trading costs and, outside a tax-sheltered account, taxes each time you rebalance.
To test your own version, clone the top 10 into the builder, set it to equal weight, and backtest it against XBI. For how often to reset the weights, see how rebalancing changes a backtest. The SOXQ holdings page shows a different way an index flattens its weights, with caps instead of equal weights.
Questions about XBI
What are XBI's top 10 holdings?
As of 20 November 2026, the ten largest positions are in the table above, led by Moderna Inc at 2.4%. Together they make up 18.7% of the fund.
How many holdings does XBI have?
XBI holds 157 companies as of 20 November 2026. The count changes as companies join or leave the index at its quarterly rebalance.
Is XBI equal weighted?
Yes, roughly. Its index sets every company to about the same weight at each quarterly rebalance, with some adjustment for the smallest and least traded companies. Between resets the weights drift with prices.
Why do XBI's top 10 holdings change so often?
Because the weights start each quarter nearly equal, the top 10 is mostly the companies whose shares rose most since the last reset. A few days of price moves can swap the names near the bottom of the list.
Can I backtest my own version of XBI's top 10?
Yes. Clone the top 10 from this page into the Indices Lab builder, change the companies or weights, choose a rebalancing rule, and backtest it against XBI. A free account is all it needs.
About this page. Holdings, weights and prices come from Indices Lab’s own data, powered by EODHD, and every number is recalculated after each market close; the text is reviewed by a person before it is published. Indices Lab is a research and educational tool: everything here is hypothetical and informational, not investment advice and not a recommendation to buy or sell any security. Past performance does not predict future results. See our methodology.